



CEO Letter – Reflections on global mRNA cancer vaccine news

Sydney, 21 August 2026

Dear Noxopharm shareholders,

Many of you will have seen the [recent news](#) regarding Moderna and Merck's highly promising data from an mRNA skin cancer vaccine trial that is currently taking place around the world.

We have received several enquiries as to what this important development means for Noxopharm, given our interest in both mRNA vaccine technology and using the immune system to target cancer, so I'd like to provide some context.

Before going any further, let me state that our reflections are purely scientific and Noxopharm-focused, rather than representing any competitive or commercial angle with Merck and Moderna.

Our first insight is that their achievement supports the scientific rationale for approaches to immuno-oncology like ours, that seek to harness and strengthen the immune system against cancer.

In technical terms, they use a personalised mRNA vaccine to generate an antigen-specific T-cell response, which is then supported by checkpoint inhibition.

At this higher conceptual level their approach is fundamentally the same as our own, even though [our asset](#) works differently as it is based on a TLR8 potentiator designed to unblind immune cells toward recognising cancer cells by amplifying innate immune activation, rather than delivering tumour-specific neoantigens.

It's best to think of the two approaches as scientifically distinct but complementary within the broader field of cancer immunotherapy.

Second, this development is further evidence that the world is moving beyond mRNA COVID vaccines into a new era of tailored mRNA vaccines for cancer and other diseases.

These emerging cancer vaccines are likely to require stronger doses, given more often, than COVID vaccines – and larger doses potentially create an inflammation issue for vaccine recipients.

Our [SOF-VAC™](#) technology aims to reduce the inflammatory side effects that come with mRNA vaccines, which could be relevant to the industry as this field develops scientifically and commercially.

At a big picture level, Moderna and Merck's ability to demonstrate clinical benefit from a personalised mRNA cancer vaccine is significant, and is likely to encourage further research, investment and development activity. It is a very exciting milestone that lifts the entire sector.

While we are of course at an earlier developmental stage, we believe our [Sofra™ technology](#) has significant potential.



Buoyed by this news, we will continue focusing on developing our pipeline, progressing our [SOF-SKN™](#) drug through clinical trials, and capitalising on the opportunity ahead of us in a rapidly evolving landscape.

Kind regards,

Olivier

Dr Olivier Laczka

CEO Noxopharm

Forward Looking Statements

This letter may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.